8 juni 2023: ASCO 2023

In de week van 2 t/m 6 juni was er weer  ASCO 2023. Hier een aantal aanbevolen abstracten gerelateerd aan verschillende vormen van kanker en van immuuntherapie tot TKR-remmers door Dr. David Henry, Clinical Professor of Medicine at Pennsylvania Hospital in Philadelphia, and member of the Advisory Board of PracticeUpdate Oncology.

Klik op de nummers van de abstracten om deze te lezen of te downloaden:

Friday, June 2, 2023; 2:45 PM–5:45 PM CDT
Oral Abstract Session
Breast Cancer—Local/Regional/Adjuvant

502 Detection of circulating tumor DNA following neoadjuvant chemotherapy and surgery to anticipate early relapse in ER positive and HER2 negative breast cancer: Analysis from the PENELOPE-B trial. N Turner, F Marmé, S-B Kim, et al

Take-Home Message

  • ctDNA is really coming on strong relative to our ability to diagnose and treat patients. Here, a report from the PENELOPE-B trial talks about the predictive potential of ctDNA in terms of future relapse. The detection of ctDNA following neoadjuvant chemotherapy and surgery was found to be associated with a very high risk of early relapse, indicating that adjuvant endocrine therapy very well may have limited efficacy.
  • ctDNA may inform early versus late relapse and may lead to earlier diagnosis and treatment or to advancing the patient to a clinical trial sooner.

Friday, June 2, 2023; 4:45 PM–5:45 PM CDT
Rapid Abstract Session
Developmental Therapeutics – Immunotherapy

2516 Association of ctDNA tumor fraction with survival in advanced non-small cell lung cancer (NSCLC) treated with maintenance durvalumab in the UNICANCER SAFIR02-Lung/IFCT1301 trial. F Dall'Olio, D Vasseur, M Karimi, et al

Sunday, June 4, 2023; 8:00 AM–11:00 AM CDT
Oral Abstract Session
Gastrointestinal Cancer—Colorectal and Anal

LBA3503 Phase III randomized clinical trial comparing the efficacy of neoadjuvant chemotherapy and standard treatment in patients with locally advanced colon cancer: The NeoCol trial. LH Jensen, M Kjaer, F Larsen, et al

Sunday, June 4, 2023; 1:00 PM–4:00 PM CDT
Plenary Session

LBA3 Overall survival analysis from the ADAURA trial of adjuvant osimertinib in patients with resected EGFR‑mutated (EGFRm) stage IB–IIIA non-small cell lung cancer (NSCLC. R Herbst, M Tsuboi, T John, et al

LBA4 SWOG S1826, a randomized study of nivolumab(N)-AVD versus brentuximab vedotin(BV)-AVD in advanced stage (AS) classic Hodgkin lymphoma (HL). A Herrera, M LeBlanc, S Castellino, et al

Take-Home Message

  • Results here may be exciting as AVD with something besides bleomycin is not very popular; but, what to pair it with? Either nivolumab or brentuximab vedotin.
  • Hopefully this study will inform.

Monday, June 5, 2023; 8:00 AM–11:00 AM CDT
Poster Session
Gastrointestinal Cancer—Colorectal and Anal

3524 Circulating tumor DNA (ctDNA) to assess response in patients with anal cancer treated with definitive chemoradiation. J Alvarez, A Cercek, N Mohan, et al

3594 Effect of trifluridine/tipiracil in combination with bevacizumab on ECOG-PS in refractory metastatic colorectal cancer: An analysis of the phase 3 SUNLIGHT trial. J Taieb, GW Prager, M Fakih, et al

Take-Home Message

  • The phase II results of the combination of trifluridine/tipiracil with bevacizumab were very positive; but, will the phase III results tell us that the combination is better in fact than trifluridine/tipiracil monotherapy?
  • The phase III results will probably lead to a change in the standard of care for third-line treatment in patients with metastatic colorectal carcinoma.

Monday, June 5, 2023; 11:30 AM–2:30 PM CDT
Oral Abstract Session
Breast Cancer—Metastatic

1003 Final overall survival (OS) analysis from the phase 3 TROPiCS-02 study of sacituzumab govitecan (SG) in patients (pts) with hormone receptor–positive/HER2-negative (HR+/HER2–) metastatic breast cancer (mBC). S Tolaney, A Bardia, F Marmé, et al

Take-Home Message

  • The availability of antibody–drug conjugates for the treatment of HR+/HER2− metastatic breast cancer has expanded treatment options for a considerable number of patients. As the goal of therapy is palliation, it is important to understand the efficacy and safety of these new agents, which will help to optimize sequencing therapies.
  • An overall survival benefit was previously reported for sacituzumab govitecan as compared with treatment of physician’s choice in the TROPICS-02 trial, and the current final overall survival analysis will be important to help further characterize the efficacy benefits seen with this potent antibody–drug conjugate.

Monday, June 5, 2023; 11:30 AM–2:30 PM CDT
Oral Abstract Session
Genitourinary Cancer—Kidney and Bladder

LBA4500 Efficacy and safety of atezolizumab plus cabozantinib vs cabozantinib alone after progression with prior immune checkpoint inhibitor (ICI) treatment in metastatic renal cell carcinoma (RCC): Primary PFS analysis from the phase 3, randomized, open-label CONTACT-03 study. T Choueiri, L Albiges, P Tomczak, et al

Take-Home Message

  • Analysis of primary progression-free survival turns up potentially practice-changing negative data with IO-TKI in the second-line setting in patients with metastatic RCC.

Monday June 5, 2023; 1:15 PM–4:15 PM CDT
Poster Session
Symptoms and Survivorship

12126 Denosumab biosimilar (LY01011) in the treatment of bone metastases in patients with solid tumors: A multicenter, randomized, double-blind, active comparator-controlled phase 3 study. M Zhao, X Hu, A Zeng, et al

Take-Home Message

  • It is interesting that denosumab now has a biosimilar. This study shows that the biosimilar is as effective as denosumab and reinforces that we don’t use this molecule enough despite phase III trials showing superior results to zoledronic acid in patients with solid tumor bone metastases.

Plaats een reactie ...

Reageer op "ASCO 2023: aanbevolen abstracten voor verschillende vormen van kanker door Dr. David Henry"

Gerelateerde artikelen